Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)

Marinus Pharmaceuticals Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	397,546	417,485	409,731	485,074	381,077	395,721
Revenue Growth (YoY)	0.59%	1.89%	-15.53%	27.29%	-3.70%	-3.82%
Cost of Revenue	137,419	141,432	128,228	148,536	117,447	122,006
Gross Profit	260,127	276,054	281,503	336,538	263,630	273,715
Selling, General & Admin	117,882	139,372	144,618	208,717	151,491	140,383
Operating Expenses	117,882	139,372	144,618	208,717	151,491	140,383
Operating Income	142,245	136,682	136,885	127,821	112,139	133,332
Interest Expense	-300	-161.5	-1,594	-6,475	-449	-1,969
Interest & Investment Income	18,270	15,463	21,665	10,732	7,360	12,006
Currency Exchange Gain (Loss)	-93.81	-133.63	-15.04	-	-	-
Other Non Operating Income (Expenses)	-122.84	-97.52	60.97	4,412	-839.85	-409.28
EBT Excluding Unusual Items	159,999	151,752	157,001	136,490	118,210	142,960
Gain (Loss) on Sale of Assets	163.2	163.2	2.28	-	-	-
Pretax Income	160,162	151,915	157,003	136,490	118,210	142,960
Income Tax Expense	32,802	30,743	31,740	27,665	23,905	28,899
Net Income	127,360	121,172	125,263	108,824	94,305	114,061
Net Income to Common	127,360	121,172	125,263	108,824	94,305	114,061
Net Income Growth	6.86%	-3.27%	15.11%	15.40%	-17.32%	37.75%
Shares Outstanding (Basic)	21	21	21	23	21	21
Shares Outstanding (Diluted)	21	21	21	23	21	21
Shares Change (YoY)	-0.01%	-	-5.00%	5.27%	-0.00%	-2.18%
EPS (Basic)	5923.94	5635.90	5826.22	4808.40	4386.40	5305.20
EPS (Diluted)	5923.94	5635.90	5826.22	4808.40	4386.40	5305.20
EPS Growth	6.86%	-3.27%	21.17%	9.62%	-17.32%	40.81%
Free Cash Flow	149,769	90,452	146,699	84,126	25,862	54,119
Free Cash Flow Per Share	6966.27	4207.10	6823.21	3717.11	1202.91	2517.18
Dividend Per Share	-	-	3000.000	-	2400.000	-
Gross Margin	65.43%	66.12%	68.70%	69.38%	69.18%	69.17%
Operating Margin	35.78%	32.74%	33.41%	26.35%	29.43%	33.69%
Profit Margin	32.04%	29.02%	30.57%	22.43%	24.75%	28.82%
Free Cash Flow Margin	37.67%	21.67%	35.80%	17.34%	6.79%	13.68%
EBITDA	154,041	149,542	150,864	-	-	-
EBITDA Margin	38.75%	35.82%	36.82%	-	-	-
D&A For EBITDA	11,796	12,861	13,980	-	-	-
EBIT	142,245	136,682	136,885	127,821	112,139	133,332
EBIT Margin	35.78%	32.74%	33.41%	26.35%	29.43%	33.69%
Effective Tax Rate	20.48%	20.24%	20.22%	20.27%	20.22%	20.21%
Revenue as Reported	397,546	417,485	409,731	485,074	381,077	395,721

Source: S&P Global Market Intelligence. Standard template. Financial Sources.